The purpose of this study is to find out if researchers can lower the chance of non-muscle invasive bladder cancer growing or spreading by using a combination of drugs called durvalumab and monalizumab. 
   
This combination of drugs has been tested in people with other cancers and was found to stabilize the cancer and stop it from spreading. However, the combination of durvalumab and monalizumab has not been tested in non-muscle invasive bladder cancer. 
   

The purpose of this study is to evaluate the safety and efficacy of IDE849 in participants with extensive stage small cell lung cancer (ES-SCLC), neuroendocrine carcinoma (NEC), and other delta-like protein 3 (DLL3)-expressing solid tumors.
   
IDE849 is experimental, which means that they are being tested and are not yet approved by the United States Food and Drug Administration (FDA).
   
In this study, IDE849 will be given intravenously (meaning through a needle in the vein directly into the blood).

This study is for female and male patients who are 18 years of age and older, have a body mass index of 30-50 kg/m2 and have had difficulties losing weight or maintaining weight loss despite prior attempts with non-surgical weight-loss methods.

The purpose of this study to is to assess the feasibility and acceptability of using a point-of-care (POC) prostate specific antigen (PSA) test to screen men for prostate cancer in a community setting.

In this study, participants will receive a fingerstick blood draw from a research nurse at the barbershop and results will be shared with the participants.
   
Participation is expected to last up to 6 months.

The purpose of this study is to evaluate the safety and effectiveness of bright light therapy for patients with melanoma and non-small cell lung cancer (NSCLC).

In this study, bright light therapy will be provided via an iPad at the participant's home for 60 minutes total.
   
Participation is expected to last 3 weeks.

This clinical trial is for adults who have relapsed/refractory acute lymphoblastic leukemia (ALL) and the Obe-Cel product prescribed by their study doctor did not meet commercial release criteria.

The purpose of this Out-Of-Specification (OOS) Obecabtagene-Autoleucel (Obe-Cel) Early Access Program (EAP) is to make Obe-Cel OOS available for adult patients with relapsed or refractory B-cell ALL who have had leukapheresis. This program will also gather real-world safety data to check how safe the experimental intervention with Obe-Cel OOS is.

This clinical trial is for adults who have blood cancer or precancerous conditions that are highly likely to turn into blood cancer.

The purpose of this study is to answer the following primary questions:

The purpose of this study is to compare the effectiveness of 6 months of HER2-targeted medications (trastuzumab with or without pertuzumab) versus 12 months of HER2-targeted medications at reducing the risk of breast cancer coming back or death in patients with early-stage HER2+ breast cancer who had a pCR after preoperative chemotherapy combined with trastuzumab.

This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach.

The purpose of this pilot study is to evaluate a new decision support tool (“COAST”), designed for people with advanced breast cancer. This tool is intended to support patients and their providers to have meaningful conversations regarding their care and treatment. Through this study, we hope to better understand and improve our support of patients in making informed choices about their treatment.

The COAST decision support tool is available in a booklet version and a website based on preference. 

This study is being done to determine if the addition of a high dose of radiation therapy extends or improves quality of life in patients with locally advanced pancreatic cancer. Locally advanced means that the cancer cannot be removed by surgery but also has not spread to other parts of the body and the tumor has either responded or is stable after chemotherapy.

We are doing this study because we want to find out if this approach is better or worse than the usual approach, which is defined as care most people get for locally advanced pancreatic cancer.